As a New Jersey-based critical care company, CytoSorbents Corporation (NASDAQ: CTSO) specializes in blood purification to treat life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery. Their flagship product, CytoSorb®, is a unique blood purification therapy that controls deadly inflammation in these critical illnesses. With current approval in the European Union and distribution in 68 countries worldwide, CytoSorb® is actively used by healthcare providers to combat life-threatening conditions.

The power of CytoSorb® lies in its innovative technology, powered by highly porous polymer beads. These biocompatible beads actively remove excessive cytokines and other inflammatory mediators from blood and bodily fluids. By utilizing pore capture and surface adsorption, CytoSorb® effectively helps restore balance and control inflammation.

CytoSorbents Corporation is committed to prioritizing the best interests of patients, families, customers, employees, and shareholders. This dedication is reflected in their ongoing research and development efforts. With a compelling product pipeline and a focus on innovation, CytoSorbents Corporation continues to provide cutting-edge solutions for critical care and lifesaving treatment